| Entries |
| Document | Title | Date |
|---|
| 20090123553 | Peptide nanostructures and methods of generating and using the same - A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid. | 05-14-2009 |
| 20090196933 | COMPOSITIONS AND METHODS FOR PREPARATION OF POORLY WATER SOLUBLE DRUGS WITH INCREASED STABILITY - The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration. | 08-06-2009 |
| 20110195126 | PEPTIDE-COATED NANOPARTICLES WITH GRADED SHELL COMPOSITIONS - A peptide-coated nanoparticle that includes a nanocrystal surrounded by a graded shell that is composed of at least two different semiconductor molecules. At least one peptide is attached to the surface of the graded shell to render the nanoparticle biocompatible. The nanocrystal core and graded shell are optionally annealed with ultra violet radiation prior to and/or after attachment of the peptide(s). | 08-11-2011 |
| 20090202651 | Antigen specific fluorescent nanoparticles - The present invention relates, in general, to nanoparticles and, in particular, to nanoparticles coated with, for example, peptides, proteins, and/or carbohydrates, and to methods of producing and using same. The invention further relates to kits comprising the coated nanoparticles. | 08-13-2009 |
| 20130078308 | ENCAPSULATION DEVICE, MEDICAL CAPSULES, AND ENCAPSULATION METHOD - An encapsulation device includes: a fluid injection device that injects a first liquid forming a core; a liquid film holder that holds in film form a second liquid forming a shell containing the core; and a liquid contact device that makes the shell in contact with a third liquid, in which the first liquid is injected toward a liquid film of the second liquid retained by the liquid film holder to form a core, the core is wrapped with the second liquid on passing through the liquid film of the second liquid, thereby forming the shell, and the shell is made in contact with the third liquid to induce chemical reaction. | 03-28-2013 |
| 20130034610 | HYDROPHOBIC NANOTUBES AND NANOPARTICLES AS TRANSPORTERS FOR THE DELIVERY OF DRUGS INTO CELLS - Methods and materials for delivering biologically active molecules to cells in vitro or in vivo are provided. The methods and materials use carbon nanotubes or other hydrophobic particles, tubes and wires, functionalized with a linking group that is covalently bound to the nanotubes, or, alternatively, to the biologically active molecule, such as a protein. The biologically active molecule is preferably released from the nanotube when the complex has been taken up in an endosome. | 02-07-2013 |
| 20090304801 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE - Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of making and using such formulations. The formulations are particularly useful in aerosol and injectable dosage forms, and comprise nanoparticulate benzodiazepine, such as lorazepam, and at least one surface stabilizer. The formulations are useful in the treatment of status epilepticus, treatment of irritable bowel syndrome, sleep induction, acute psychosis, and as a pre-anesthesia medication. | 12-10-2009 |
| 20080248123 | Nanoparticulate anticonvulsant and immunosuppressive compositions - Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer. | 10-09-2008 |
| 20130064895 | Amphiphilic Peptides and Peptide Particles - The inventions provided herein relate to amphiphilic peptides and particles comprising the amphiphilic peptides. Such amphiphilic peptides and particles described herein can be used as a delivery system, e.g., for therapeutic or diagnostic purposes, or as cell penetration vehicles or cell transfection agents. | 03-14-2013 |
| 20090238886 | Retro-Inversion Peptides That Target GIT Transport Receptors and Related Methods - Retro-inverted forms of GIT targeting agents that target specific receptor sites in vivo and/or promote uptake of active agents and/or enhance active site delivery across the GIT into the systemic circulation are provided. These retro-inverted peptides and compositions containing these retro-inverted peptides can be used to deliver an active agent, such as a drug or a drug-containing nano- or microparticle for treatment of a condition in a subject in need of the drug, in vivo. Additionally, the invention provides antibodies which are capable of immunospecifically binding the retro-inverted peptides. | 09-24-2009 |
| 20130101672 | NANOCONJUGATES AND NANOCONJUGATE FORMULATIONS - The invention provides a drug-polymer nanoconjugate that includes a drug covalently bonded to a polymer. The nanoconjugate can include a block copolymer coating and/or an albumin coating. The drug of the drug-polymer nanoconjugate can be one or more of a variety of therapeutic agents linked to the polymer through ether or thioether linkages formed from hydroxyl or thiol groups of the drug. The albumin coating can substantially or completely retard or prevent aggregation of the nanoconjugates in solid form or in solution. The invention further provides compositions that include a plurality of drug-polymer nanoconjugates, as well as methods for using the drug-polymer nanoconjugates, such as in therapeutic or diagnostic applications. | 04-25-2013 |
| 20130115296 | METHODS FOR TREATING HEPATOCELLULAR CARCINOMA - The present invention provides methods and compositions for treating hepatocellular carcinoma (HCC) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating HCC comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent, such as an agent that inhibits microtubule disassembly. | 05-09-2013 |
| 20130115295 | Rare Earth-Doped Up-Conversion Nanoparticles for Therapeutic and Diagnostic Applications - This invention provides a composition matter comprising rare earth-doped up-conversion nanoparticles (UCNPs) encapsulated with a silica shell. In one embodiment, a photosensitizer is incorporated into the silica shell. In another embodiment, the composition further comprises a targeting molecule. In still another embodiment, a small interfering RNA (siRNA) molecule is also attached to the silica shell with the targeting molecule. The invention further provides methods for synthesizing such compositions and for using them in therapeutic and diagnostic applications. These applications use infrared or near infrared activation to excite the UCNPs. | 05-09-2013 |
| 20130122100 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF - Nanoparticles comprising a prodrug and prodrugs linked to phospholipids, wherein the linkages facilitate release of the prodrugs from the nanoparticles to sites within a target cell or cell membrane by fusion of the particle and the cell membrane are disclosed. Also disclosed are methods for producing and using the nanoparticles and their constituents. | 05-16-2013 |
| 20120237605 | Multifunctional Metal Nanoparticles Having A Polydopamine-Based Surface and Methods of Making and Using the Same - The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging. | 09-20-2012 |
| 20110280944 | FIBROUS MICROCAPSULES AND METHODS OF ASSEMBLY AND USE THEREOF - The present invention relates to assembly of peptide amphiphiles and biopolymers into fibrous microcapsules, and uses thereof. In particular, the present invention provides devices, compositions, and methods for interfacial self-assembly of peptide amphiphiles and biopolyments into fibrous microcapsules, and uses thereof. | 11-17-2011 |
| 20090258076 | WATER-SOLUBLE MAGNETIC OR METAL OXIDE NANOPARTICLES COATED WITH LIGANDS, PREPARATION METHOD AND USAGE THEREOF - This invention provides water-soluble magnetic or water-soluble metal oxide nanoparticles, which are coated with phase transfer ligands having an adhesive region, an adhesive region-crosslinking region, or an adhesive region-reactive region, and also provides a method of preparing water-soluble magnetic or metal oxide nanoparticles, the method including (1) synthesizing water-insoluble magnetic or metal oxide nanoparticles in an organic solvent; (2) dissolving the water-insoluble magnetic or metal oxide nanoparticles in a first solvent and dissolving a phase transfer ligand in a second solvent; and (3) mixing the two solutions achieved in step (2) to thus exchange the surface of the water-insoluble magnetic or metal oxide nanoparticles with the phase transfer ligand. Further, the water-soluble magnetic and water-soluble metal oxide nanoparticles coated with the phase transfer ligand can be used in various fields, including the separation and detection of materials, the diagnosis and treatment of diseases, and the decomposition of microorganisms and contaminants. | 10-15-2009 |
| 20120189702 | CELL THERAPY FOR TREATMENT OF LIVER FAILURE - Disclosed are methods for treating liver failure in a subject comprising transplanting hepatocytes or stem or progenitor cells in an extrahepatic site in the subject in an amount sufficient to provide liver support and/or induce liver regeneration, where the transplanted hepatocytes or stem or progenitor cells are used along with extracellular matrix-coated microcarriers. | 07-26-2012 |
| 20110293728 | PHOTOSENSITIZER-METAL NANOPARTICLE COMPLEX AND COMPOSITION CONTAINING THE COMPLEX FOR PHOTODYNAMIC THERAPY OR DIAGNOSIS - Provided are a photosensitizer-metal nanoparticle complex and a composition for photodynamic therapy or diagnosis having the same. The complex includes a photosensitizer, a metal nanoparticle, and a backbone linking the photosensitizer with the metal nanoparticle. The backbone has a polypeptide substrate capable of being specifically degraded by a protease. When the complex is administered to a patient, fluorescence and production of reactive oxygen species from the conjugated photosensitizers are inhibited in normal tissues due to the resonance energy transfer between the photosensitizer and metal nanoparticles, but in tumor tissues, fluorescence and production of reactive oxygen species from the released photosensitizers are activated, thereby effectively destroying the tumor tissues. In addition, the selective fluorescence in the tumor tissues can further improve accuracy of tumor diagnosis using the protease-activatable photosensitizer-metal nanoparticle complex. | 12-01-2011 |
| 20100233277 | BIODEGRADABLE POLYMER SCAFFOLD AND PROCESS FOR PREPARATION THEREOF - The present invention relates to a process for preparation of a biodegradable polymer scaffold using biodegradable polymer, surfactant and alcohol. The biodegradable polymer scaffold obtained from the process disclosed is useful for tissue engineering, therapeutic compound delivery and/or wound dressing. | 09-16-2010 |
| 20120107407 | BONE GRAFT AND BIOCOMPOSITE FOR PROSTHETIC DENTISTRY - A bone graft or biocomposite for treating osseous defects and neogenesis of bone which is a composite of a biodegradable polymer and granules of beta-tricalciumphosphate, further comprising as active ingredient and embedded in the biodegradable polymer a physiologically effective amount of underglycosylated recombinant human BSP as a muti-dental clathrate with a basic organic compound which simulataneously is active as a plasticizer for the biodegradable polymer. The biocomposite is moldable and shapeable, hardens rapidly in situ when placed by surgery or prosthetic dentistry and which furthers osseous repair and the healing of damage or diseased tissues and lesions. | 05-03-2012 |
| 20080311213 | Topical Formulations Containing Sporopollenin - Topical formulation containing an active substance which is chemically or physically bound to, or encapsulated within, an exine shell of a naturally occurring spore. The active substance can be released from the exine shell on application to a living or non-living surface. The invention may be used to provide gradual release of the active substance over a period of time subsequent to application of the formulation to the surface. | 12-18-2008 |
| 20100209518 | MICRO-PARTICLES, BLOOD-SUBSTITUTE AND METHOD FOR FORMING SAME - A method for forming micro-particles is provided. The method includes the steps of: —providing a first solution which includes at least an anion; —providing a second solution which includes at least a cation; —mixing the first solution with the second solution in presence of at least a first compound for forming porous templates, wherein the porous templates are formed by precipitation of a salt which includes the anion and the cation and wherein the first compound is at least partially incorporated in the porous templates; and—at least partially cross-linking the first compound in the porous templates. | 08-19-2010 |
| 20080274202 | Compositions and Method for Brain Specific Targeted Delivery of Therapeutic Agents - Disclosed are methods and compositions for delivering a therapeutic agent to target organs or tissues, such as brain. The methods and compositions use bone marrow stem cells, monocytes, macrophages or microglial cells to deliver the therapeutic agent associated with nanoparticles to the target organ or tissue. | 11-06-2008 |
| 20080305173 | AMORPHOUS DRUG BEADS - The present inventive subject matter relates to amorphous drug beads comprising an amorphous active drug and an organic surfactant having improved solubility, absorption and wettability characteristics. The present inventive subject matter further relates to methods of preparing the amorphous drug beads, wherein molten drug beads are subject to a cooling step with or without shear. | 12-11-2008 |
| 20090311335 | COMBINATION OF A TRIPTAN AND AN NSAID - A composition of a triptan and particles of a NSAID. The NSAID particles having an effective average particle size of less than 2000 nm and at least one surface stabilizer adsorbed on the surface thereof. The NSAID component of the composition, in a comparative pharmacokinetic testing with a non-particulate NSAID in the same dosage strength and form, exhibits a shorter time to T | 12-17-2009 |
| 20110014297 | MULTIMODAL THERAPEUTIC HYBRID PARTICLE COMPLEX AND SYSTEM - A multiple layer microbubble drug delivery system, multiple layer microbubble drug delivery vehicle, method thereof and fabrication method are disclosed. The microfluidic drug delivery system for producing multiple layer microbubbles includes a first inlet which receives a gas and directs the gas into a central stream, a second inlet which receives a first liquid containing a drug substance and flow focuses the first liquid around the gas, a third inlet which receives a second liquid and flow focuses the second liquid around the first liquid and a fourth inlet which receives a third liquid and flow focuses the third liquid around the second liquid. The multiple layer microbubble drug delivery vehicle includes a gas core, a first liquid layer containing a drug and surrounding the gas core, a second liquid layer surrounding the first liquid layer to stabilize the first liquid layer and a plurality of particles outside the second liquid layer. | 01-20-2011 |
| 20110268807 | Biodegradable Microspheres and Methods of Use Thereof - The present invention provides biodegradable microspheres, compositions comprising a subject biodegradable microsphere, and methods of using a subject biodegradable microsphere for delivery of an agent to a site in an individual. | 11-03-2011 |
| 20090081306 | MICROENCAPSULATED MATERIALS AND METHOD OF MAKING SAME - A method of forming microspheres of a bioactive material, such as a protein polymer or drug by nebulizing a solubilized form of a material to be encapsulated and an encapsulating material, such as albumin, in a stirred chilled solvent system comprising a vegetable oil, mineral oil and/or a lower alcohol such that the formed microspheres demonstrate intracellular bioactivity when taken up by macrophages. | 03-26-2009 |
| 20120070502 | METHODS OF TREATING CANCER - The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid. | 03-22-2012 |
| 20080317863 | Pharmaceutical Compositions Useful in the Transmucosal Administration of Drugs - There is provided pharmaceutical compositions in the form of homogeneous interactive mixtures, which compositions comprise a pharmacologically-effective amount of an active ingredient in the form of microparticles of a size between about 0.5 μm and about 10 μm, which particles are attached to the surfaces of larger carrier particles with a size range of between about 10 and about 100 μm. The carrier particle material is preferably bio- and/or mucoadhesive in its nature. | 12-25-2008 |
| 20090252807 | Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives - The present invention is directed to compositions comprising a nanoparticulate prostaglandin derivative, preferably limaprost or a salt or derivative thereof, having improved bioavailability. The nanoparticulate prostaglandin derivative particles of the composition have an effective average particles size of less than about 2000 nm and are useful in the treatment of ischemic symptoms. The invention also relates to a controlled release composition comprising a prostaglandin derivative, such as limaprost alfadex, or a nanoparticulate prostaglandin derivative, such as limaprost or a salt or derivative thereof, that in operation delivers the drug in a pulsed or bimodal manner for the treatment of ischemic symptoms. | 10-08-2009 |
| 20090252808 | CONTROLLED RELEASE OF BIOLOGICAL ENTITIES - A process is provided for releasably encapsulating a biological entity. The process comprise combining a solution of a surfactant in a non-polar solvent with a precursor material and the biological entity to form an emulsion. The emulsion comprises a polar phase dispersed in a non-polar phase, wherein the polar phase comprises the biological entity. The particles comprising the biological entity are then formed from the polar phase. | 10-08-2009 |
| 20100015238 | Powder Compositions for Inhalation - A pharmacological powder for inhalation comprising fine particles of a drug and particles of a force-controlling agent, wherein the particles of said force-controlling agent are disposed on the surface of the active particles as either a particulate coating, or as a continuous or discontinuous film. The powder may further comprise particles of a carrier material for supporting the drug particles. The force-controlling agent may be selected from: amino acids, peptides and polypeptides having a molecular weight of from 0.25 to 1000 KDa; phospholipids; titanium dioxide; aluminium dioxide; silicon dioxide; starch; and salts of fatty acids. Also disclosed is a method of making such a powder for inhalation comprising mixing a force-controlling agent with particles of one or more pharmacologically active materials to obtain a mixture in which the particles of said force-controlling agent are disposed on the surface of the active particles as either a particulate coating, or as a continuous or discontinuous film. The mixing step may be achieved by sieving, mixing or blending, micronising and/or co-micronising the particles of one or more pharmacologically active material and particles of force-controlling agents. | 01-21-2010 |
| 20100260857 | Enzyme delivery systems and methods of preparation and use - This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders. | 10-14-2010 |
| 20100278924 | Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents - Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties. | 11-04-2010 |
| 20110059181 | METHODS FOR DRUG DELIVERY COMPRISING UNFOLDING AND FOLDING PROTEINS AND PEPTIDE NANOPARTICLES - The present invention provides preparation methods of protein nanoparticles for in vivo delivery of pharmacologically active agents, wherein said methods are to encase pharmaceutically active agents into proteins or peptides to form nanoparticles by unfolding the protein, and subsequently refolding or assembling the protein to produce a pharmacologically active agent encased within a protein nanoparticle. | 03-10-2011 |
| 20100255108 | Combination Treatment of Cancer With Cetuximab and Tetrac - Provided herein are compositions and methods for treating cancer by increasing the inhibitory effect of cetuximab on HIF1α expression by administering cetuximab in combination with anti-angiogenic thyroid hormone analogs such as tetrac or triac. | 10-07-2010 |
| 20110123632 | Nanoscale Adjuvants and Related Pharmaceutical Compositions and Methods - Described herein are nanoscale adjuvants for use in pharmaceutical compositions. In one embodiment, a pharmaceutical composition includes: (a) a vaccine; and (b) a nanoscale adjuvant including an aluminum compound in the form of clusters having a peak size in the sub-micron range. | 05-26-2011 |
| 20110111040 | POLYELECTROLYTE-ENCAPSULATED GOLD NANOPARTICLES CAPABLE OF CROSSING BLOOD-BRAIN BARRIER - A gold-creatine nanoparticle is described, preferably covered with albumin, together with a process for its preparation and its use as medicament, in particular for the treatment of stroke. Said gold nanoparticle is capable of crossing the blood-brain barrier. | 05-12-2011 |
| 20090214663 | Virus coated nanoparticles and uses thereof - The present invention discloses method to coat nanoparticles with viral envelope containing specific proteins. The present invention also discloses that such viral envelope coated nanoparticles can be targeted to specific cells and cellular entry pathway, thereby permitting their use as vaccines, in targeted delivery of therapeutic products and in the study of virus adsorption, cell penetration and viral entry pathways. | 08-27-2009 |
| 20090214662 | SURFACE-LAYER PROTEIN COATED MICROSPHERES AND USES THEREOF - The invention provides surface-layer protein coated microspheres for delivery of a therapeutic agent to the intestine. These surface-layer protein coated microspheres generally include a core encapsulated by a microsphere which is coated by surface layer protein. The core includes a therapeutic agent, such as a defensin. The invention also includes methods of making and using the surface-layer protein coated microspheres of the invention for administering therapeutic agents to a subject in need thereof. The invention also includes pharmaceutical dosage units that include the surface-layer protein coated microspheres of the invention. The invention further includes various labeled defensins for use in the study of the properties and actions of defensins, and further includes the use of defensins, particularly HD5α in the treatment of inflammatory conditions of the bowel, such as Crohn's disease. | 08-27-2009 |
| 20110052708 | METHODS AND FORMULATIONS FOR THE DELIVERY OF PHARMACOLOGICALLY ACTIVE AGENTS - In accordance with the present invention, novel formulations have been developed which are much more effective for the delivery of hydrophobic drugs to patients in need thereof than are prior art formulations. Invention formulations are capable of delivering more drug in shorter periods of time, with reduced side effects caused by the pharmaceutical carrier employed for delivery. | 03-03-2011 |
| 20110151012 | COMPOSITIONS COMPRISING POORLY WATER SOLUBLE PHARMACEUTICAL AGENTS AND ANTIMICROBIAL AGENTS - The present invention provides compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, and an antimicrobial agent, wherein significant microbial growth is inhibited in the composition. The amount of the antimicrobial agent in the composition may be below the level that induces a toxicological effect or at a level where a potential side effect can be controlled or tolerated. Also provided are compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, a sugar, and optionally an antimicrobial agent. Methods of using the compositions are also provided. | 06-23-2011 |
| 20110052710 | NOVEL NANOPARTICLES FOR DELIVERY OF ACTIVE AGENTS - Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications. | 03-03-2011 |
| 20110052709 | NOVEL NANOPARTICLES FOR DELIVERY OF ACTIVE AGENTS - Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications. | 03-03-2011 |
| 20100062073 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES COMPRISING ENTERIC POLYMERS CASEIN - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and an enteric polymer, and casein. | 03-11-2010 |
| 20100003336 | VESICLES OF SELF-ASSEMBLING BLOCK COPOLYMERS AND METHODS FOR MAKING AND USING THE SAME - Vesicles of self-assembling block copolymers, e.g., diblock copolypeptides, as well as methods of making and using the same. Vesicles of the invention have a shell made up of block copolymers that include an intracellular transduction hydrophilic domain and a hydrophobic domain. In certain embodiments, the vesicles include an encapsulated active agent, e.g., a diagnostic or therapeutic agent. The vesicles find use in a variety of different application, including the intracellular delivery of active agents, e.g., diagnostic and therapeutic agents. | 01-07-2010 |
| 20080286371 | Immunogenical Complex Formed by Vaccinal Antigens Encapsulated by Nanostructured Mesoporous Silica - The present invention relates to a product named “immunogenical complex”, which comprises an adjuvant characterized by solid particles of highly ordinated nanostructured mesoporous silica, preferably, SBA-15 Silica, and vaccinal antigens of several natures, encapsulated in the referred to adjuvants. The immunogenical complex of the present invention allows the presentation of the antigens that compose it to lymphocytes, in a safe, gradual and extended way, which leads to a more efficient immunological memory, increases the immunogenicity of the antigen and improves the production of antibodies. This ensures an efficient immunological protection with fewer amounts of antigens and/or less repetitions of vaccinal doses. In addition, the characteristics of the immunogenical complex of the present invention promotes effective immunity induction, homogeneous in “god and bad respondent” individuals. | 11-20-2008 |
| 20080268063 | Coated Controlled Release Polymer Particles as Efficient Oral Delivery Vehicles for Biopharmaceuticals - A composition for delivering an active agent to a patient. The composition includes a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core. The polymer may include covalently linked poly(ethylene glycol) chains, and the mucoadhesive coating may be selected to facilitate transfer of the particle through the intestinal mucosa. A molecular weight and cross-link density of the polymer may be selected such that the polymer core will decompose in a predetermined time interval. The fraction of the dose of the drug entering the system at circulation during the predetermined time interval may be between about 0.25% and about 25%. The composition may be formulated as a plurality of nanoparticles or microparticles that are combined with a pharmaceutically acceptable carrier to produce an edible or inhalable drug product. | 10-30-2008 |
| 20110256228 | Solid Forms for Tissue Repair Background of the Invention - This invention provides coral-based scaffolds for cartilage repair, and instruments for insertion and utilization of same within a site of cartilage repair. | 10-20-2011 |
| 20120121716 | PHARMACEUTICAL COMPOSITION OF AN ANTHRACYCLINE - The present invention relates to pharmaceutical composition containing nemorubicin hydrochloride incorporated in microspheres. The compositions are useful for chemoembolisation, particularly for loco regional treatment of tumors. | 05-17-2012 |
| 20110165255 | MALIGNANT TUMOR HEAT THERAPY KIT COMPRISING ANTI-REGULATORY T CELL ANTIBODY AND MAGNETIC FINE PARTICLES AND HEAT THERAPY METHOD THEREOF - The present invention discloses a heat therapy kit for malignant tumor treatment that comprises a pharmaceutical agent containing anti-regulatory T cell antibody and a pharmaceutical agent containing magnetic fine particles, and a heat therapy method that uses that kit. | 07-07-2011 |
| 20100196495 | DELIVERY OF FLU ANTIBODIES TO SURFACES IN CONTACT WITH AIR - The invention relates to a method, composition and inhaler system for treatment or prophylaxis of influenza infection in one or more subjects by applying to a surface selected from air filters, sick room surfaces and respiratory mucosal membranes at least one immune material selected from antibodies and fragments thereof which bind a least one Influenza A antigen selected from the group consisting of H1, H3 and H5, the immune material being derived from hyperimmune milk products such as hyperimmune colostrum said hyperimmune milk products being prepared by inoculation of mammals with antigen composed of a least one Influenza A antigen selected from H1, H3 and H5. | 08-05-2010 |
| 20090202650 | METHODS OF TREATING CANCERS - A method of treating cancer. The method includes introducing an effective amount of an oxidative catalyzing agent including titanium oxide, zinc oxide, zirconium oxide, tungsten oxide or tin oxide into a biological entity, and irradiating the biological entity with a ray. The oxidative catalyzing agent produces hydroxyl or hydrogen peroxide radicals after irradiation with the ray thereon. | 08-13-2009 |
| 20090175951 | NANOPARTICULATE COMPOSITIONS OF IMMUNOSUPPRESSIVE AGENTS - Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such as a pharmaceutical agent, and at least one surface stabilizer. The component chemical compound exhibits chemical stability, even following prolonged storage, repeated freezing-thawing cycles, exposure to elevated temperatures, or exposure to non-physiological pH conditions. | 07-09-2009 |
| 20110189299 | PHARMACEUTICAL COMPOSITION CONTAINING SURFACE-COATED MICROPARTICLES - The invention provides a pharmaceutical composition that can be used for efficient administration of low-molecular weight drugs and polymeric compounds such as peptides and proteins by methods other than injection, as well as a method for producing the composition. The pharmaceutical composition is for transmucosal administration and comprises (a) a drug having a positive or negative charge at a predetermined pH, (b) a pharmaceutically acceptable small particle and (c) a pharmaceutically acceptable surface-coating polymer capable of being electrically charged at the pH, wherein the surface of the small particle is coated by the surface-coating polymer, the drug is immobilized on the surface of the small particle via the surface-coating polymer, and a complex is formed by a noncovalent interaction between the small particle and the surface-coating polymer and a concurrent electrostatic interaction between the surface-coating polymer and the drug. | 08-04-2011 |
| 20100028450 | TOLEROGENIC BIODEGRADABLE ARTIFICIAL ANTIGEN PRESENTING SYSTEM - An artificial antigen presenting system is presented. The herein presented microspheres combine negative regulators individually or at varying combinations along with MCH molecules and can induce antigen specific tolerance. The herein described methods provide for the construction of artificial biodegradable microsomes containing MHC: peptide complexes, accessory molecules, co-stimulatory molecules, adhesion molecules, and other molecules relevant to T cell binding or modulation. Additionally, the present invention is directed to compositions and methods for treating conditions which would benefit from modulation of T cell response, for example, autoimmune disorders, allergies, cancers, viral infections, and graft rejection. | 02-04-2010 |
| 20120308661 | ORALLY ADMINISTRABLE PHARMACEUTICAL PELLET OF EPIDERMAL GROWTH FACTOR - The present invention comprises a pellet of epidermal growth factor and methionine or K | 12-06-2012 |
| 20120308660 | NANOCOATINGS FOR BIOLOGICAL MATERIALS - The present invention provides formulations comprising nanocoated biological materials (e.g., viral particles), methods for producing powders comprising nanocoated biological materials, and powders produced from such formulations and methods. Also provided are pharmaceutical compositions comprising the present formulations or dried powders, and vaccines comprising the present formulations or dried powders. The nanocoated biological materials typically display superior stability for either direct use in a formulation or in drying processes to produce a powder material, wherein the coated materials are typically more tolerant to environmental stress (e.g., chemical, thermal, and/or mechanical stress) during storage or drying processes. | 12-06-2012 |
| 20090022808 | Coated Hyaluronic Acid Particles - The present invention generally relates to particles comprising hyaluronic acid, wherein the particles are coated or encapsulated with a coating. The coating preferably comprises a polymer, protein, polysaccharide, or combination thereof that decreases the rate of degradation of the hyaluronic acid once the particles are placed in an aqueous environment, such as inside mammalian skin. The compositions of the present invention comprising such coated hyaluronic acid are useful for soft tissue augmentation, and are particularly useful as dermal fillers. | 01-22-2009 |
| 20110117204 | IMMUNOLOGICALLY ACTIVE COMPOSITIONS - This invention provides a microparticle carrier system comprising of one or more proteins, peptides, nucleic acids, carbohydrates, lipids or other bioactive substances with or without targeting molecules attached. In addition, the invention also provides immune modulatory compositions and methods of eliciting protective immune responses both in uninfected and infected hosts as well as the induction of immune tolerance. | 05-19-2011 |
| 20100143484 | ORAL SUBMICRON PARTICLE DELIVERY SYSTEM FOR PROTEINS AND PROCESS FOR ITS PRODUCTION - The invention provides a novel submicron system for the oral administration of proteins. An effective oral carrier for proteins should shield its content against the gastrointestinal tract proteases and be capable of facilitating the uptake of the protein drug across the gastrointestinal epithelium. The present invention relates to production of gelled particles which comprises a protein drug susceptible to enzymatic degradation by enzymes and acid conditions in the stomach, a polymeric matrix which undergoes precipitation-swelling process, and two-layer-coating materials which are themselves capable of enhancing absorption of said drug across the intestinal mucosal tissues and of inbihiting degradation of said drug by gastric enzymes. Insulin-loaded particles with appropriate submicron size for gastrointestinal absorption were made of natural occurring polymers by emulsification-based method and proved to be gastric pH and protease protective. Effects on glycemia were observed during 14 h after their oral single administration to rats, achieving 42% of pharmacological activity compared to subcutaneous administration. Postprandial rise in blood glucose was suppressed and insulinemia levels increased by a factor of seven. The relative oral bioavailability of insulin calculated over 8 h by comparison with a subcutaneous injection of free insulin was 34%. | 06-10-2010 |
| 20110305765 | PREPARATION AND METHODOLOGY OF SILK FIBROIN NANOPARTICLES - Disclosed are nanoparticles for delivery of drugs and/or nutraceuticals that include a fibroin polypeptide and a drug or nutraceutical, wherein the nanoparticle has a diameter of about 1 nm to about 500 nm, and compositions of the nanoparticles. The nanoparticles may further include a chitosan, or a proteoglycan such as decorin. Also disclosed are methods of delivering a drug and/or nutraceutical to a subject that involve administering to the subject nanoparticles of the present invention. Also disclosed are methods of making the nanoparticles of the invention, and kits that include the nanoparticles of the invention. | 12-15-2011 |
| 20130011484 | Cannabinoid Receptor Binding Agents, Compositions, and Methods - A composition comprising a cannabinoid receptor binding agent attached to a particle for the treatment of skin conditions. The particle may be a nanoparticle, such as nanocrystalline cellulose. The particle may further be modified with functional moieties. Drug delivery properties may be modified by coating the particles or using vesicles to deliver the cannabinoid receptor binding agent and particle. A substrate may be used to deliver the composition to the skin. | 01-10-2013 |
| 20090238885 | PROTEIN ENCAPSULATED PARTICLES - Particles that are encapsulated by protein are provided. Also a method for preparing protein encapsulated particles involving spraying and drying of an activated protein solution is provided. The protein encapsulated particles are particularly suited for food, feed, cosmetic and pharma applications. | 09-24-2009 |
| 20110318423 | Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content - The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction. | 12-29-2011 |
| 20120114759 | PEPTIDE/PARTICLE DELIVERY SYSTEMS - Polymeric nanoparticles, microparticles, and gels for delivering cargo, e.g., a therapeutic agent, such as a peptide, to a target, e.g., a cell, and their use for treating diseases, including angiogenesis-dependent diseases, such as age-related macular degeneration and cancer, are disclosed. Methods for formulating, stabilizing, and administering single peptides or combinations of peptides via polymeric particle and gel delivery systems also are disclosed. | 05-10-2012 |
| 20100028451 | SILK MICROSPHERES FOR ENCAPSULATION AND CONTROLLED RELEASE - A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in β-sheet structure dominant silk microsphere structures having about 2 μm in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments. | 02-04-2010 |
| 20120015037 | FUNCTIONALIZED NANOPARTICLE, METHOD FOR PREPARING THE SAME AND APPLICATION THEREOF - The present invention relates to a new type of functionalized nanoparticles for drug delivery, comprising a type of polymer nanoparticles, a polymer stabilizer coating, and a drug, wherein said polymer stabilizer coating is coated on the surface of said type of polymer nanoparticles, and said drug is conjugated to said polymer stabilizer coating. The present invention also relates to a method for preparing the nanoparticles; and provides a method for treating an ischemic or degenerative disease, comprising administrating an effective amount of the type of functionalized nanoparticles to a subject. | 01-19-2012 |
| 20090110739 | Targeted cancer chemotherapy using synthetic nanoparticles - Compositions and methods for delivery of a pharmaceutical to an individual. Delivery vehicles are provided in a formulation of a pharmaceutical that is encapsulated in a synthetic self assembled nanoparticle that includes a lipid binding protein and a lipid monolayer. The interior of the particle represents a hydrophobic core region where lipophilic highly-water insoluble drug molecules may be incorporated. In contrast to liposomes, that include an aqueous interior core surrounded by phospholipid bilayer, the drug carrier nanoparticle described here is composed of a monolayer and a hydrophobic interior. | 04-30-2009 |
| 20110091562 | NANOGELS FOR CELLULAR DELIVERY OF THERAPEUTICS - The various embodiments of the present disclosure relate generally to nanogels for the cellular delivery of therapeutics and methods of using the same. More particularly, the various embodiments of the present invention are directed to systems and methods for the targeted treatment of neoplastic using nanogel-based technologies. In an embodiment of the present invention, a nanogel-based delivery system comprises: a nanogel comprising a crosslinked polymer particle; and an active agent contained substantially within the nanogel, wherein the active agent is non-covalently associated with the nanogel. | 04-21-2011 |
| 20120315335 | SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM - A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided. | 12-13-2012 |
| 20120128779 | PROCESS FOR PRODUCING PROTEIN MICROPARTICLES - The present invention relates to a process for producing protein microparticles in dilute organic acid solutions and in the absence of an alcohol such as ethanol. The microparticles are formed by dissolving a cereal prolamin protein in a concentrated organic acid solution with agitation and then diluting the solution with an aqueous solution. Protein microparticles having vacuoles are thus formed. The protein microparticles may be used to form powders, films, coatings, matrices, scaffolds and the like. Complete films can be formed from the protein microparticles of the invention. | 05-24-2012 |
| 20120164232 | CONSTRUCT COATED WITH VIRUS COAT-CONSTITUTING PROTEIN AND METHOD FOR PRODUCING SAME - Disclosed is a construct comprising a virus coat protein usable as a carrier for drug delivery adaptable to various drugs. Specifically disclosed is a construct coated with a virus coat protein, comprising a virus coat protein and a construct coated therewith, wherein the virus coat protein is attached to the surface of the construct to form a layer of the protein thereon. | 06-28-2012 |
| 20120135081 | HYDROPHOBINS FOR DISPERSING ACTIVE AGENTS - In the field of drug or nutrient administration novel particles and formulations thereof are provided. Said particles each have a core comprising active agent and at least partial coating comprising proteins, selected from hydrophobins. Preferable hydrophobins belong to class I or class II. Said particles exhibit enhanced characteristics, for example dispersibility or solubility. Here is also disclosed two methods for producing said particles in nanoscale, of which one utilizes precipitating and another wet milling. | 05-31-2012 |
| 20100173001 | Metal Ion-Treated Biocompatible Polymers Useful for Nanoparticles - Disclosed are methods for forming particles useful for the treatment of hyperproliferative disease. The method includes providing a bioactive component and a metal ion-treated biocompatible polymer component; coating the bioactive component with a surfactant having an HLB value of less than about 6.0 units under conditions which form a coated bioactive component; associating the coated bioactive component with the a metal ion-treated biocompatible polymer under conditions which associate the coated bioactive component with the metal-ion treated biocompatible polymer to form a particle, where the particles have an average diameter of less than about 50 nanometers. Related compositions and methods to treat disease using the particles are also disclosed. | 07-08-2010 |
| 20120076862 | METHODS OF ENHANCING DRUG DELIVERY AND EFFECTIVENESS OF THERAPEUTIC AGENTS - The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”). Also provided are pharmaceutical compositions, article of manufacture, and kits useful for methods described herein. | 03-29-2012 |
| 20120177743 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 07-12-2012 |
| 20120225126 | SOLID STATE SYNTHESIS METHOD OF SILVER NANOPARTICLES, AND SILVER NANOPARTICLES SYNTHESIZED THEREBY - Disclosed are a solid state synthesis method of silver nanoparticles, and silver nanoparticles synthesized thereby. The method includes mixing a silver salt and a water soluble polymer acting as both a reducing agent and a protecting agent to produce a solid mixture, and milling the solid mixture by a high-speed vibration milling process to form silver nanoparticles within the water soluble polymer. According to the present invention, silver nanoparticles can be easily and simply produced in a solid state through high speed vibration milling, thereby reducing costs for industrial production and transportation of silver nanoparticles. In addition, the synthesized silver nanoparticles can be used for a long time since the silver nanoparticles are stable in a solid state for 1 year or more. | 09-06-2012 |
| 20090061006 | Layered Nanoparticles for Sustained Release of Small Molecules - Nanoparticle compositions and methods are disclosed for the sustained release of small molecules, such as pharmaceutical compounds in vivo, for example ligand-lytic peptide conjugates. The construction of the nanoparticles helps to prevent self-aggregation of the molecules, and the consequent loss of effectiveness. The system employs layer-by-layer self-assembly of biocompatible polyelectrolyte layers, and layers of charged small molecules such as drug molecules, to form a multilayer nanoparticle in which the drug or other small molecule itself acts as one of the alternating charged layers in the multilayer assembly. The small molecules can then be released over time in a sustained manner. The LbL nano-assemblies can specifically target cancers, metastases, or other diseased tissues, while minimizing side effects. | 03-05-2009 |
| 20120082728 | MULTIFUNCTIONAL STEALTH NANOPARTICULES FOR BIOMEDICAL USE - The present invention relates to the field of drug delivery nanosystems. More precisely, the present invention concerns a copolymer with advantageous properties for the outer coating of various nanoparticles. Said copolymer comprises at least three types of monomers with stealthy, coupling and therapeutic properties respectively, as well as an optional fourth type of monomers with targeting properties. The present invention also relates to core-shell or hollow shell nanoparticles coated by an external layer of the copolymer according to the invention. Several types of core-shell nanoparticles are envisaged. The invention also concerns methods for preparing said nanoparticles, as well as pharmaceutical compositions or medicaments comprising them. | 04-05-2012 |
| 20120189703 | Enzyme Delivery Systems and Methods of Preparation and Use - This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders. | 07-26-2012 |
| 20120189701 | COMBINATION THERAPY WITH THIOCOLCHICINE DERIVATIVES - The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a colchicine or thiocolchicine dimer and an anti-VEGF antibody. The method may further comprise administering an effective amount of a taxane. The colchicine or thiocolchicine dimer and the taxane (such as paclitaxel) may be present in the form of nanoparticles, such as nanoparticles comprising the drug and a carrier protein such as albumin. | 07-26-2012 |
| 20120258176 | NANOPARTICLES FOR PROTEIN DRUG DELIVERY - The invention discloses particulate complexes composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively charged poly-glutamic acid substrate form an electrostatic network enabling improved loading the bioactive agent. | 10-11-2012 |
| 20120231082 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF - In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein. | 09-13-2012 |
| 20110003004 | Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces - Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle. | 01-06-2011 |
| 20120328703 | SWELLABLE PARTICLES FOR DRUG DELIVERY - Swellable particles for delivery of a drug or other working agent to the pulmonary system are provided. The swellable particles include a dehydrated (dry) aerodynamic particle diameter of 5 μm or less to enable delivery to the respiratory tract, such as for example to the tracheo-bronchial airways of the upper respiratory tract and/or to the alveolic regions of the deep lung, and a hydrated particle diameter that is greater than 6 μm volume mean diameter to retard or prevent their phagocytosis by the macrophages present in airways of the respiratory tract. | 12-27-2012 |
| 20100233276 | COMPOSITIONS IN POWDER FORM MADE OF SOFT AGGLOMERATES OF A MICRONIZED DRUG AND OF A TWO-COMPONENTS EXCIPIENT, AND PROCESS FOR THEIR PREPARATION - The described agglomeration of drug microparticles blended with excipient microparticles is a technique for the size enlargement of micronized products that could be damaged by granulation or compaction techniques. These agglomerates can be used as oral prompt or delayed-release dosage forms administered as they are or dispersed in a liquid. The composition and quantity of the excipient microparticles resulted to be the crucial factors for the agglomerate quality. Therefore, adjusting the content of surface-active agent between 8-20%, of the excipient microparticles it is possible to agglomerate microparticles of drugs that could not be agglomerated per se. Increasing the surfactant concentration in the spray-dried excipient microparticles or increasing the fraction of these excipient microparticles in the blend, the agglomeration was improved. The spray drying technique concentrates the surface-active agent on the microparticle surface. By tumbling, the surface-active agent present on microparticles excipient surface was spread to fill the inter-particle interstices of drug particles giving rise to more resistant agglomerates. This phenomenon occurred also by vibration; the production in this case was quicker. | 09-16-2010 |
| 20110045093 | PHARMACEUTICAL COMPOSITION AND PROCESS COMPRISING VEGETABLE PROTEOLYTIC ENZYMES IN SUPRAMOLECULAR NANOPARTICLES, FOR THE TREATMENT OF PEYRONIE'S DISEASE, CONNECTIVE TISSUE DISEASES AND USE - This invention refers to a pharmaceutical composition applied to the therapy of Peyronie's disease, in connective tissue diseases. The composition comprises, in its formulation, vegetable proteolytic enzymes encapsulated in the supramolecular nanoparticles. | 02-24-2011 |
| 20110045092 | CASEIN PARTICLES ENCAPSULATING THERAPEUTICALLY ACTIVE AGENTS AND USES THEREOF - Casein particles, such as micelles or clusters thereof, having encapsulated therein hydrophobic and/or water insoluble therapeutically active agents such as hydrophobic chemotherapeutic agents, which are otherwise administered parenterally, are disclosed. Pharmaceutical compositions containing the casein particles and uses thereof in the treatment of cancer and other conditions treatable by the encapsulated therapeutically active agent are also disclosed. Further disclosed are processes of preparing the casein particles. The disclosed casein particles are useful for orally delivering the therapeutically active encapsulate and can further be used for controllably releasing the agents in the gastrointestinal tract. | 02-24-2011 |
| 20120269895 | DENDRITIC PIC MICELLES WITH BIOACTIVE PROTEINS - A polyion Complex (PIC) polymeric micelle is formed by interaction between a bioactive protein and a dendritic block copolymer of opposite charge. The conventional low stability of PIC micelles with bioactive proteins vis-à-vis ionic strength is offset by the stability provided by the dendritic block. The overall process for preparing the micelles is facilitated by the simplicity of the drendritic block copolymer synthesis. | 10-25-2012 |
| 20110236493 | POROUS MATERIALS - A consumer care composition or a food composition comprising a mesoporous microparticulate material wherein at least some of the pores of the material are loaded with at least one ingredient and the loaded mesoporous microparticulate material is encapsulated by a capping layer is described. | 09-29-2011 |
| 20110159103 | Novel Preparation of an Enteric Release System - Hydrophobic liquids are microencapsulated by an enteric matrix in an environment substantially free of organic solvents. The process includes forming an emulsion of the enteric material and hydrophobic liquid in water, titrating the emulsion with an acid to form a particulate precipitate and optionally coating the particulate with a combination of enteric material and plasticizer. | 06-30-2011 |
| 20110262546 | GOLD NANOPARTICLES COATED WITH POLYELECTROLYTES AND ALBUMIN - It is described a gold nanoparticle coated with from two to five layers of a combination of a polyelectrolyte having amino functionality and a polyelectrolyte having sulfonic functionality, or with one single layer of said polyelectrolyte having amino functionality, preferably polyallylamine, or sulfonic functionality, preferably polystyrenesulfonic, characterized in that said nanoparticle comprises an outer layer of albumin. It is also described the process for its preparation, its use as carriers intended to cross blood-brain barrier and its use as medicament, in particular for treatment of neurodegenerative diseases, more in particular of diseases caused by protein aggregates, such as prion diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Also described are pharmaceutical compositions comprising said nanoparticle. | 10-27-2011 |
| 20110274761 | POLYMER CARRIER - Compositions and methods for delivering bioactive agents, such as vitamins, hormones, nutrients and drugs, by stabilizing and or solubilizing these agents in a polymer matrix. The carrier polymers can be used in drug delivery and are useful for delivery of small molecules. The carrier polymers also can be used in scaffolds for regenerative medicine | 11-10-2011 |
| 20120087985 | SMALL PEPTIDE SEQUENCES FOR STABILIZING BIOMOLECULES - Disclosed herein are a class of small molecules, referred to as Small Peptide Sequences (SPS), that can stabilize biomolecules, particles containing the SPS and biomolecules, and compositions and methods of making the particles. The SPS are composed solely of amino acids common to humans and too small to trigger an immunological response (typically less than seven amino acids in total) and which will self assemble into particles sufficiently small to stay in liquid suspension at a first pH, typically a non-physiological pH, but which dissociate, releasing the biomolecule entrapped therein into solution, at a second pH, typically a physiological pH. The particles contain a SPS and a biomolecule, wherein the biomolecule is entrapped with the particle, immobilized on the surface of the particle, or combinations thereof. The particle releases the biomolecule upon contact with physiological fluids. | 04-12-2012 |
| 20120093937 | ENCAPSULATED LIVER CELL COMPOSITION - Microcapsules including a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact with a liver cell stimulating amount of erythropoietin. | 04-19-2012 |
| 20120093936 | METHOD AND DEVICE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH INFLAMMATION OR UNDESIRABLE ACTIVATION OF THE IMMUNE SYSTEM - The present invention relates to methods and compositions for use in the treatment of specific medical conditions. The compositions of the invention comprise blood serum preparations, such as activated blood serum preparations. The present invention also relates to the use of such blood serum preparations for the treatment of diseases and disorders associated with inflammation and/or undesirable activation of the immune system, such as paradentosis, abortus habitualis, colitis ulcerosa, polymyalgia rheumatica, whiplash-associated disorders, endometriosis, adeomyosis and unexplained infertility. | 04-19-2012 |
